ArticleCase reports in surgery2016
Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management.
Article in Case reports in surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Glucagonoma and Glucagonoma Syndrome: An Updated Review.Clinical endocrinology · 2025Review
- The Importance and Challenges of Early Diagnosis of Paraneoplastic Skin Syndromes in Cancer Detection-A Review.Cancers · 2025Review
- Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas.Endocrine oncology (Bristol, England) · 2025Article
- Case report: Surgical treatment and literature review of a recurrent case of glucagonoma.Frontiers in oncology · 2024Article
- Skin manifestations of neuroendocrine neoplasms: review of the literature.Postepy dermatologii i alergologii · 2022Review
- Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma.Scientific reports · 2022Article
- How Many Times Can One Go Back to the Drawing Board before the Accurate Diagnosis and Surgical Treatment of Glucagonoma?Diagnostics (Basel, Switzerland) · 2022Article
- Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.Histology and histopathology · 2021Review
- Acute onset of necrolytic migratory erythema mimicking an erythema multiforme.Postepy dermatologii i alergologii · 2020Article
- Glucagonoma: From skin lesions to the neuroendocrine component (Review).Experimental and therapeutic medicine · 2020Review
- Article
- Unremitting chronic skin lesions: a case of delayed diagnosis of glucagonoma.Journal of community hospital internal medicine perspectives · 2019Article
- Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.Medicine · 2017Article
- MANIFESTATIONS OF GLUCAGONOMA SYNDROME.AACE clinical case reportsArticle
- Diarrhea: a missed D in the 4D glucagonoma syndrome.Autopsy & case reportsArticle
- Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.Clinical imagingArticle
- Glucagonoma of the pancreas: diagnostic approach and therapeutic algorithm for a rare nosological entity.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rarity of glucagonoma imposes a challenge with most patients being diagnosed after a long period of treatment for their skin rash (months-years). Awareness of physicians and dermatologists of the characteristic necrolytic migratory erythema often leads to early diagnosis. Early diagnosis of glucagonoma even in the presence of resectable liver metastases may allow curative resection. Herein, we present a typical case of glucagonoma treated at our center and review the literature pertinent to its management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.